논문검색
Author Ju Chae Park, M.D., Hyeon Gyeung Yoo, Ph.D., Hong Su Kim, Min A Jung, Mi Ha Kim, Sang Won Han, Kee Oh Chay, M.D., Boo Ahn Shin, M.D., Bong Whan Ahn M.D. and Young Do Jung, M.D.
Place of duty Chonnam National University Research Institute of Medical Sciences, Chonnam National University Medical School, Gwangju, Korea
Title SB203580, a P38 MAPK Inhibitor, Blocks in vitro Invasion by Human Gastric SNU-638 Cells
Publicationinfo Cancer Research and Treatment 2002 Dec; 034(06): 426-431.
Key_word Stomach neoplasm, P38 milogen-activated protein kinase, Urokinase-type plasminigen activator, Invasion
Full-Text
Abstract Purpose: The role of P38 mitogen-activated protein kinase (MAPK) in gastric cancer invasion has not yet been determined. In this study, we examined the effects of SB203580, a specific P38 MAPK inhibitor, on the in vitro invasion of gastric cancer and upon the molecules involved in this process.

Materials and Methods: Human gastric cancer SNU-638 cells were maintained in RPMI 1640 supplemented with 10% FBS. BIOCOAT matrigel invasion chambers were used to examine in vitro invasiveness, zymography for gelatinase activity, CAT assay for uPA promoter activity and Western and Northern blotting to determine protein and mRNA levels, respectively.

Results: Treatment of SNU-638 cells with SB203580, a specific P38 MAPK inhibitor, reduced in vitro invasi-

veness, dose-dependently. SB203580 treatment was found to decrease both mRNA expression and uPA promoter activity in gastric SNU-638 cells. In vitro invasion of SNU-638 cells was partially abrogated by uPA-neutralizing antibodies. The activities of MMPs were not significantly altered by SB203580.

Conclusion: Our results suggest that P38 MAPK is a potential therapeutic target for inhibiting uPA-dependent gastric tumor invasiveness and metastasis. (Cancer Research and Treatment 2002;34:426⁣431)

저 자 박주채, 유현경, 김홍수, 정민아, 김미하, 한상원, 채기오, 신부안, 안봉환, 정영도